Organiser: ITE Group Time: October 1st – October 3rd, 2025 address:Brovarskiy Avenue 15, Kiev, Ukraine, 02000 Exhibition hall: Kiev International Exhibition Center Product range: Medical Equipment: Diagnostic instruments and devices, X-ray diagnostic equipment, radiation medical devices, medical electromechanical equipment, therapeutic instruments, orthopedic and rehabilitation equipment, hospital and clinic equipment, medical services, sterilization and convalescent equipment, disposable medical supplies and instruments Medical Emergency: Emergency equipment, mobile hospitals, wheelchairs, ambulances Ophthalmology: Ophthalmic equipment, glasses, lenses Dentistry: Dental instruments, equipment, disposable medical products Pharmaceuticals: Intermediates, pharmaceutical products, vaccines, enzymes, homeopathic medicines, mineral and vitamin preparations, hormones, pharmaceutical synthesis products, bioactive additives, pediatric dietary nutrition, chemically synthesized foods, pharmaceutical formulation production equipment, bioresearch About PUBLIC HEALTH: The Ukraine Kiev Medical Equipment Exhibition (PUBLIC HEALTH) aims to provide visitors with the latest technologies and information regarding the pharmaceutical and pharmaceutical industries from Ukraine’s public health sector. This is particularly focused on the use of ...
Kelun PharmaceuticalIt was disclosed on the evening of June 12 that the chemical drug “Cefazolin Sodium/Sodium Chloride Injection for Injection” of the company’s subsidiary Hunan Kelun Pharmaceutical Co., Ltd. recently obtained drug registration approval from the State Food and Drug Administration. Disclosures show that cefazolin sodium is a classic drug for anti-infective treatment. It is currently widely used in clinical practice for various perioperative preventive medications and treatment of respiratory tract, skin and soft tissue, bone and joint infections caused by sensitive bacteria. It is also the only cephalosporin recognized by WHO as the preferred choice for surgical prevention. Cefazolin Sodium/Sodium Chloride Injection for Injection is a Class B national medical insurance product. In 2024, sales of cefazolin sodium injection in China will reach 1.35 billion yuan. The Cefazolin Sodium/Sodium Chloride Injection for Injection for which Kelun Pharmaceutical has obtained a drug registration certificate is a powder-liquid double-chamber bag, with ...
June 12, Hybio Pharmaceutical released the record of investor relations activities. HY3003 is a GLP-1R/GIPR/GCGR triple-target receptor agonist screened by Hanyu Pharmaceuticals and its partners using AI peptide chip technology for weight loss indications. As of this week, the preclinical optimal candidate compound screening and API process development have been completed, and the API pilot scale-up stage has officially begun. In addition to triple-target weight loss drugs, the company also has 1.1-class innovative drugs. HY3000 nasal spray, which is indicated for the prevention of coronavirus infection, is currently in the phase III clinical trial stage. In terms of the exploration of innovative cannabidiol (CBD) drugs , the company has established a partnership with Sinopharm In-depth cooperation is carried out in the fields of research and development of innovative cannabidiol (CBD) drugs , integration of peptide and small nucleic acid drug technologies, and commercial promotion. In terms of clinical progress, the ...
On June 12, Sailon (002898) announced that its wholly-owned subsidiary Hunan Sailon Pharmaceutical (Changsha) Co., Ltd. recently obtained the Drug Registration Certificate for Famotidine Injection approved and issued by the State Drug Administration. The drug is a Class 3 chemical drug, with an injection form and specifications of 1ml: 10mg and 2ml: 20mg. The registration certificate number is 2025S01758/2025S01757, and it is valid until June 9, 2030. Famotidine injection is listed as a national basic medical insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)” Class A drugs, mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer. The approval of the drug will further enrich the company’s preparation varieties, but the specific sales situation is still affected by a variety of internal and external environmental factors, and there is a certain degree of uncertainty. In the first quarter of 2025, Sailon achieved revenue of 54.09 million yuan ...
June 12th, Eli Lilly announced that Mufengda (multi-dose prefilled pen for tilpotide injection) is available in China. This is a new injection device launched by Eli Lilly after the successful launch of tilpotide at the beginning of the year . Tilpotide injection is the world’s first and currently the only once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved for T2DM and long-term weight management. The launch of the multi-dose prefilled pen is to increase supply in China and meet the needs of more patients. 网址:https://finance.eastmoney.com/a/202506123428962957.html
Drugdu.com expert’s response: I. Saudi Arabia SASO Certification: This certification involves pre-shipment inspection and conformity verification for products imported into the Saudi market, ensuring that imported goods comply with Saudi quality standards. SABER Certification: A system introduced by Saudi Arabia for online application of customs clearance certificates. It is used for product registration, issuance, and obtaining Certificates of Conformity (COC). SABER certification includes a Product Certificate (PC) and a Shipment Certificate (SC). All goods exported to Saudi Arabia must apply for an SC through the SABER system before the goods arrive at the port. II. Gulf Cooperation Council (GCC) Countries GCC Certification (G-MARK Certification): Applicable to the six Gulf countries, including Saudi Arabia, the United Arab Emirates, and Kuwait. It requires products to comply with the unified Gulf Standards (GSO). Products such as low-voltage equipment, toys, and building materials are involved, and they need to pass tests conducted by GSO-authorized ...
Drugdu.com expert’s response: I. Clinical Research Data KL264-01 Study: In the subgroup analysis targeting EGFR-mutated non-small cell lung cancer (NSCLC) patients, the objective response rate (ORR) of sacituzumab tirumotecan as a monotherapy reached as high as 55%, with a median progression-free survival (PFS) of 11.1 months. These results were significantly superior to those in EGFR wild-type patients, who had an ORR of 24% and a median PFS of 5.3 months. SKB264-II-08 Study: Among 64 previously treated EGFR-mutated NSCLC patients, sacituzumab tirumotecan achieved an ORR of 34%, a disease control rate (DCR) of 84%, a median duration of response (DOR) of 9.6 months, a median PFS of 9.3 months, and a 1-year overall survival (OS) rate of 79%. OptiTROP-Lung03 Study: The sacituzumab tirumotecan group demonstrated a confirmed ORR of 45.1%, significantly higher than the 15.6% in the docetaxel group. The median PFS was 6.9 months, significantly longer than the 2.8 months ...
Policy Tendence National Health Commission: Promote the construction of compact urban medical groups in 81 pilot cities across the country On June 10th, the relevant person in charge of the National Health Commission stated that in accordance with the overall requirement of “major illnesses should not leave the province, general illnesses should be solved in cities and counties, and daily illnesses should be solved at the grassroots level”, firstly, the construction of national medical centers and national regional medical centers should be promoted, which is commonly referred to as the “dual center” construction. Secondly, we should focus on the construction of urban medical groups. Promote the construction of compact urban medical groups in 81 pilot cities across the country, and promote the sharing of medical resources. In addition, by the end of 2024, 2188 counties (cities, districts) across the country have promoted the construction of close county-level medical communities, ...
No.1 Kexing Pharmaceutical plans to transfer 100% equity of Tong’an Pharmaceutical for 15 million yuan On June 10th, Sinopharm announced that it plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tong’an Pharmaceutical Co., Ltd. to Guangxi Zhuang Autonomous Region Institute of Materia Medica Co., Ltd. for a transfer price of 15 million yuan. According to the announcement, Tong’an Pharmaceutical has not actually conducted business in recent years. Currently, it mainly holds approval numbers for 20 drugs, including 19 traditional Chinese medicine varieties such as Vitamin C Yinqiao tablets. After the transaction is completed, Sinopharm will no longer hold equity in Tong’an Pharmaceutical, and Tong’an Pharmaceutical will no longer be included in the company’s consolidated financial statements. Comment: The sale of equity in Tong’an Pharmaceutical by Kexing Pharmaceutical is beneficial for the company to continue focusing on the biopharmaceutical field, improve core competitiveness, reduce operational risks, and is ...
By Dennis Thompson HealthDay ReporterTUESDAY, June 10, 2025 (HealthDay News) — Blood tests can detect evidence of cancer three years earlier than the disease would otherwise be diagnosed, a new small-scale pilot study says. The test — called a multicancer early detection (MCED) test — looks for genetic material that’s shed by tumors into the bloodstream. The test revealed cancer DNA that was circulating in some patients’ blood up to three-and-a-half years prior to their diagnosis with cancer, according to results recently published in the journal Cancer Discovery. “Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome,” said senior researcher Nickolas Papadopoulos, a professor of oncology at the Ludwig Center at Johns Hopkins in Baltimore. “Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers,” he added in a news release. For the study, researchers assessed ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.